Inhibikase Therapeutics
Atlanta, US · Delaware corporation
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics for pulmonary arterial hypertension (PAH). It is publicly traded on Nasdaq under the ticker IKT.
Founders & leadership
MH
Milton H. Werner Ph.DFounder
JF
Joseph Frattaroli, C.P.A.Executive
DB
Dennis BermanNamed on SEC filing
GD
Gisele DionNamed on SEC filing
Board
PG
Paul Grint, M.D.Board director
RF
Roy Freeman M.D.Board director
Reported raises · per SEC filings
Form D private placements$4.2M disclosed across 1 of 2 rounds · 2023–2024
▶$8MofferedJun 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$8MofferedJun 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul GrintDirector
- Milton H. WernerExecutive Officer, Director
- Gisele DionDirector
- Roy FreemanDirector
- Garth Lees-RolfeExecutive Officer
- Dennis BermanDirector
- Offering amount
- $8M
- Sales commissions
- $340K
- Placement agents
- Maxim Group LLC
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedFeb 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$4.2MraisedFeb 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph Frattaroli, C.P.A.Executive Officer
- Paul Grint, M.D.Director
- Milton H. Werner Ph.DExecutive Officer, Director
- Dennis BermanDirector
- Gisele DionDirector
- Roy Freeman M.D.Director
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- Sales commissions
- $294K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
TradingView14 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Robinhood14 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits12 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Public12 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Seeking Alpha11 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Inhibikase Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 9 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $385.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $3.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $3.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $284.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $265.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Inhibikase Therapeutics do?
- Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics for pulmonary arterial hypertension (PAH). It is publicly traded on Nasdaq under the ticker IKT.
- Who founded Inhibikase Therapeutics?
- Inhibikase Therapeutics was founded by Milton H. Werner Ph.D.
- How much funding has Inhibikase Therapeutics raised?
- Inhibikase Therapeutics has disclosed $4.2M raised across 1 of its 2 known rounds.
- Where is Inhibikase Therapeutics headquartered?
- Inhibikase Therapeutics is headquartered in Atlanta, US.